Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,090 across all filing types
Latest filing 2018-01-26 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
关于注销部分募集资金专户的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the cancellation of a portion of the company's fundraising special account. It details the original fundraising amount, the use of the funds, and the closure of the specific fundraising account. There is no financial statement or comprehensive financial report included, nor is it a report publication announcement. The content focuses on the management and update of capital raised and its usage, which aligns with updates on company fundraising activities or capital structure changes. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is short (1754 characters), and it is not a report publication or certification, so it is not RPA or RNS.
2018-01-26 Chinese
关于公司获得医疗器械注册证的进展公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a medical device registration certificate from the China Food and Drug Administration (CFDA). It details the product information, registration certificate number, validity period, and the impact of this certification on the company. The document is short (1389 characters) and serves as a formal notification of a regulatory approval rather than a financial or operational report. It does not contain financial data, management discussion, or detailed report content. Therefore, it fits best as a Regulatory Filing (RNS), which is a general regulatory announcement category for filings that do not fit other specific categories.
2018-01-22 Chinese
关于公司获得医疗器械注册证的提示性公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (1120 characters) from a company about obtaining a medical device registration certificate from the CFDA. It includes product information, impact on the company, and a risk warning. There are no financial statements, no detailed financial data, no management discussion of results, nor is it a report or presentation. The document is an official company announcement about a regulatory approval event, not a financial report or meeting material. It is not a report publication announcement since it does not mention any report being published or attached. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about a significant company event that does not fit other specific categories.
2018-01-19 Chinese
以自筹资金预先投入募投项目的鉴证报告（截至2017年7月28日）
Audit Report / Information Classification · 95% confidence The document is a verification report (鉴证报告) issued by a registered accounting firm regarding the company's use of self-raised funds to pre-invest in projects intended to be funded by raised capital. It includes an auditor's opinion on the management's special explanation about the pre-investment of funds, referencing compliance with Shenzhen Stock Exchange guidelines. The document contains no full financial statements or comprehensive financial performance data typical of an Annual Report (10-K) or Interim Report (IR). Instead, it is a standalone audit-related attestation focused on a specific financial verification task. The document length is under 5,000 characters and is a formal auditor's verification report, which fits the category of Audit Report / Information (AR). FY 2017
2018-01-17 Chinese
关于2018年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the company's expected related party transactions for the fiscal year 2018. It details the nature, estimated amounts, and approvals related to daily related party transactions, including procurement from an affiliated company. The document includes board meeting resolutions, independent director opinions, and supervisory board reviews. It does not contain financial statements or comprehensive financial data but rather focuses on disclosure of related party transaction estimates and compliance with regulatory requirements. The document length is 3713 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best into the category of Regulatory Filings (RNS), as it is a regulatory announcement about related party transactions and not a full financial report or other specific filing type.
2018-01-15 Chinese
中信证券股份有限公司关于公司2018年度预计日常关联交易的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding the expected daily related-party transactions of Xiamen Aide Biomedical Technology Co., Ltd. for the year 2018. It includes descriptions of the related-party transactions, pricing policies, board and independent director opinions, and the sponsor's verification opinion. The document references regulatory guidelines and compliance with Shenzhen Stock Exchange rules. It is not a full annual report, audit report, or earnings release, but rather a specialized verification opinion related to related-party transactions, which is a type of regulatory filing. The document length is 3817 characters, which is relatively short and focused on a specific compliance matter rather than a comprehensive financial report. Therefore, it fits best under Regulatory Filings (RNS) as it is a compliance and verification document related to regulatory requirements and not a full financial report or announcement of a report.
2018-01-15 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.